Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor and CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma
NCT05322330Phase 2Completed
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Feb 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor in B-cell non-Hodgkin lymphoma (B-NHL), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Overall Response Rate at 12 months, Duration of Response at 12 months and 1 more. Started Feb 2022; status: completed.
02
Drugs
selinexor
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT05322330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05322330.